# Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival

> **NCT01574170** · PHASE4 · COMPLETED · sponsor: **Institut Claudius Regaud** · enrollment: 267 (actual)

## Conditions studied

- Metastatic Breast Cancer Starting a Third Line Chemotherapy

## Interventions

- **OTHER:** Construction of a prognostic score (non-drug intervention types)

## Key facts

- **NCT ID:** NCT01574170
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-18
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01574170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01574170, "Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01574170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*